<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105336</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-105</org_study_id>
    <secondary_id>2017-001912-13</secondary_id>
    <nct_id>NCT03105336</nct_id>
  </id_info>
  <brief_title>A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma</brief_title>
  <acronym>ZUMA-5</acronym>
  <official_title>A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll approximately 160 adult subjects who have relapsed or refractory (r/r)&#xD;
      iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease&#xD;
      responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is&#xD;
      made from the subjects own white blood cells which are genetically modified and grown to&#xD;
      fight cancer. An objective response rate of 70% is targeted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll approximately 160 adult subjects who have relapsed or refractory (r/r)&#xD;
      iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease&#xD;
      responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is&#xD;
      made from the subjects own white blood cells which are genetically modified and grown to&#xD;
      fight cancer. An objective response rate of 70% is targeted.&#xD;
&#xD;
      All enrolled subjects will be screened for eligibility then will undergo leukapheresis to&#xD;
      collect white blood cells for manufacturing. In preparation for the infusion with&#xD;
      axicabtagene ciloleucel, subjects will undergo conditioning chemotherapy with&#xD;
      cyclophosphamide and fludarabine for 3 days to help the study treatment be effective. After&#xD;
      the product is manufactured and conditioning chemotherapy period is complete, subjects will&#xD;
      be infused with axicabtagene ciloleucel and then monitored in a hospital for a minimum of 7&#xD;
      days. Subjects will be followed by their study doctor for continued monitoring of the safety&#xD;
      and effectiveness of the study treatment for approximately 3 months after receiving treatment&#xD;
      and then will be followed for safety for up to an additional 15 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">February 2037</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate per central read</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Complete response (CR) + partial response (PR) per the Lugano Classiciation (Cheson et al, 2014).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR Rate per central read</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>CRR is defined as the incidence of CR as best response to treatment by the Lugano Classification (Cheson et al, 2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>DOR is defined only for subjects who experience an objective response and is the time from the first objective response to disease progression per (Cheson et al, 2014) or disease-related death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per (Cheson et al, 2014) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>OS is defined as the time from KTE-C19 infusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of anti-CD19 CAR T cells in blood</measure>
    <time_frame>At enrollment, Day 7, Week 2, Week 4, Month 3, Month 6, Month 12, Month 18, Month 24, annually up to year 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of cytokines in serum</measure>
    <time_frame>At enrollment, prior to axicabtagene ciloleucel infusion on Day 0, Day 3, Day 7, Week 2, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants experiencing anti-axicabtagene ciloleucel antibodies</measure>
    <time_frame>At enrollment, Week 4, Month 3, every 3 months up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing clinically significant changes in lab values</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next Therapy</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Time from axi-cel infusion date to the start of the subsequent new lymphoma therapy or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate among participants with 3 or more lines of prior therapy</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Complete response (CR) + partial response (PR) per the Lugano Classiciation (Cheson et al, 2014) for participants with 3 or more lines of prior therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate among those participants with 3 or more lines of prior therapy</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Complete response rate is defined as the incidence of CR as best response to treatment by the Lugano Classification (Cheson et al, 2014) for participants with 3 or more lines of prior therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>axicabtagene ciloleucel</intervention_name>
    <description>A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
    <other_name>Yescarta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Individual has [follicular lymphoma or marginal zone lymphoma that has progressed&#xD;
             after at least 2 lines of treatment with combination chemoimmunotherapy] (e.g.&#xD;
             R-bendamustine, R-CHOP).&#xD;
&#xD;
          2. Individual has [measurable disease].&#xD;
&#xD;
          3. Individual has no known presence or history of central nervous system (CNS)&#xD;
             involvement by lymphoma.&#xD;
&#xD;
          4. If individual is on conventional systemic therapy or systemic inhibitory/stimulatory&#xD;
             immune checkpoint therapy, individual is able to stop conventional therapy 2 weeks or&#xD;
             5 half-lives, whichever is shorter, or immune checkpoint therapy 3 half-lives prior to&#xD;
             planned leukapheresis.&#xD;
&#xD;
          5. Individual has Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and&#xD;
             adequate renal, hepatic, pulmonary, and cardiac function&#xD;
&#xD;
          6. Individual is not pregnant or breastfeeding (female individuals only) and is willing&#xD;
             to use birth control from the time of consent through 6 months following chimeric&#xD;
             antigen receptor (CAR) T cell infusion (both male and female individuals).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Transformed follicular lymphoma (FL) or marginal zone lymphoma (MZL)&#xD;
&#xD;
          2. Small lymphocytic lymphoma&#xD;
&#xD;
          3. Histological Grade 3b FL&#xD;
&#xD;
          4. Individual will have undergone autologous transplant within 6 weeks of planned&#xD;
             leukapheresis or has undergone allogeneic transplant.&#xD;
&#xD;
          5. Individual has evidence of involvement of the heart by lymphoma or requirement for&#xD;
             urgent therapy due to ongoing or impending oncologic emergency (e.g. mass effect,&#xD;
             tumor lysis syndrome, etc.)&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center - John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center (URMC)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

